A

Alnylam Pharmaceuticals Inc

ALNYNASDAQHEALTHCARE
$295.06+1.20 (+0.41%)
Market closedPrev close $293.86

Price action

Daily adjusted bars

1signal overlaid
Prior signal1

Snapshot

Key stats

AV May 30
Market cap
$39.47B
P/E ratio
74.09
Forward P/E
31.65
Beta
0.30
52W range
$284.28 - $495.55
Dividend yield
--
Volume
4.29M
Sector
HEALTHCARE

Analyst

Consensus price target

Live

Current

$295.06

Target

$445.81

+150.75 (+51.1%) upside12mo horizon

AlphaYou verdict

Insider Cluster

LONGLive
14/ 100
WeakScore 14 / 100Issued May 15, 2026

Smart-money signal on ALNY this 14d.

  • Smart money5.0/40
  • Fundamentals6.0/35
  • Technicals1.0/15
  • Macro2.0/10

Receipts

Recent signals for this ticker

  • LONGMay 15
    Insider Cluster

    Smart-money signal on ALNY this 14d.

    Public Recommendation·Checkpoints pending

Smart money

Insider, fund, and political flow

Live6 receipts
  • filing 13f fund flow

    TWO SIGMA INVESTMENTS, LP increased position ($659.3M) (+223%)

    +4.0
  • filing nport p fund flow

    American Funds Insurance Series holds $455.3M (NPORT-P 2025-12-31)

    +4.0
  • filing nport p fund flow

    Janus Investment Fund (legacy active) holds $18.2M (NPORT-P 2026-09-30)

    +4.0
  • filing 13f fund flow

    Citadel Advisors LLC holds $15.3M (13F 2025-12-31)

    +4.0
  • filing nport p fund flow

    Janus Detroit Street Trust (active ETFs) holds $313K (NPORT-P 2026-10-31)

    +4.0
  • filing 13f fund flow

    FMR LLC (Fidelity) holds $6.3B (13F 2025-12-31)

    +3.0

Top trader activity

Pending

Copy-trading signal layer from real US-equity operators. Wires in once the CopyTrading feed is mapped to US-stock tickers.

BTC Astro risk regime

Pending

Cross-asset risk timing overlay. Used as context only, never a primary stock source.

Reputation

Sources and actors behind this ticker

Source families

  • SEC EDGAR 13F

    Source family

    D7

    92

    +1.17%

    60.9% hit

    D15

    pending

    D30

    pending

Actors and filers

Checkpoint ledger

Public recommendation outcomes

Pending

No public recommendation checkpoints have landed for this ticker yet.

D7 appears first, then D15 and D30 as the call matures.

Each row is a public recommendation. Alpha columns compare the frozen issued price with SPY, QQQ, and sector ETF checkpoints when available.

Raw source coverage

Primary-source receipt chain

100.0%
Linked
1
Events
1
Signals
1
Recs
Source coverage1/1
SEC EDGAR 13F1/1 linked
Recent source events
  • SEC EDGAR 13F

    FILING 13F FUND FLOW · May 15· source

    raw linked

Fundamentals

Valuation, quality, growth

Live

Valuation

  • P/E74.09
  • Forward P/E31.65
  • P/S9.21
  • P/B36.70

Quality

  • Profit margin12.6%
  • Operating margin23.0%
  • ROE90.4%
  • ROA10.1%

Growth

  • Revenue YoY--
  • Earnings YoY--
  • Beta0.30
  • Dividend yield--

Technicals

Trend, momentum, levels

Live

Trailing returns

  • 5d+1.08%
  • 20d-0.16%
  • 60d-0.68%

Trend vs SMAs

  • vs SMA50+0.62%
  • vs SMA200-0.23%

52w range position

$284.285%$495.55

Computed from AV daily adjusted bars. No options-flow, IV, or order-book signals on this page yet.

Macro

Sector + regime context

Live
  • macro regime shift

    VIX 17.3 (mild) as of 2026-05-14

    +17.3
  • macro regime shift

    10y-2y spread 47bps (flattish) as of 2026-05-14

    +0.5
  • macro regime shift

    Industrial Production 102.5 (mild expansion) as of 2026-04-01

    +102.5
  • macro regime shift

    Initial claims 211,000 vs 26w mean (ratio 0.99, neutral)

    +1.0
  • macro regime shift

    CPI YoY 3.95% (hot vs Fed target)

    +4.0

Earnings

EPS beat / miss history

Live
$3.50$2.20$0.91$-0.38$-1.68Q2 '24Q4 '24Q2 '25Q4 '25Q1 '26
BeatMissMatchEstimate

Debate

Key issues

Live
  • Bullish view

    • TWO SIGMA INVESTMENTS, LP increased position ($659.3M) (+223%)
    • American Funds Insurance Series holds $455.3M (NPORT-P 2025-12-31)
    • Janus Investment Fund (legacy active) holds $18.2M (NPORT-P 2026-09-30)
    • Citadel Advisors LLC holds $15.3M (13F 2025-12-31)

    Bearish view

    No receipts on this side yet.

Arguments are pulled from contributing receipts (Form 4 / 13F / fundamentals / macro) for this ticker. Each side carries the count of receipts behind it, not an analyst headline count.

Track record

Recommendation receipts

vs SPY

S&P 500

1 rec · 1L · 0S

Median alpha

+2.76%

Mean alpha

+2.76%

Hit rate

100.0%

Mean return

+3.65%

vs QQQ

Nasdaq-100

1 rec · 1L · 0S

Median alpha

+2.44%

Mean alpha

+2.44%

Hit rate

100.0%

Mean return

+3.65%

D7 recommendation-counted alpha. Each receipt aggregates same-day same-direction signals into one row to avoid double-counting.